Return

Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease

2026-07-08

Yutong Cai

Yuxuan Wang

Wenjing Huang

Ying Su

Ming Lei

Ruonan Jia

Chenyue Wu

Tianming Zhang

Lanlan Sun

Bihao Peng

Jintai Yu

Xiaochun Chen

Jiawei Xin

DOI：10.1002/alz.71655

Original

Save

View PDF

Abstract

En 中文

Lecanemab, the first disease-modifying therapy for Alzheimer's disease (AD), mitigates pathology primarily by clearing amyloid plaques, but its impact on peripheral immunity remains unclear.

Keywords:

Alzheimer's disease

B cells

Lecanemab

peripheral immunity

single-cell RNA sequencing

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.